Alexion Pharmaceuticals ALXN today announced that
researchers presented data from clinical trials demonstrating the
clinical benefits of chronic Soliris® (eculizumab) treatment
in patients with atypical hemolytic uremic syndrome (aHUS) as well as
new patient registry data providing further insight into optimal care
for patients with paroxysmal nocturnal hemoglobinuria (PNH) at the
American Society of Hematology (ASH) 55th Annual Meeting and Exposition
in New Orleans. Data included:
A new, comprehensive study of key aHUS biomarkers indicating that,
prior to initiation of Soliris treatment, aHUS patients have severe
ongoing terminal complement activation and inflammation with increased
thrombotic risk. The study further indicates
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in